α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: Results from the CONKO-001 study

British Journal of Cancer

Volumn 111, Issue 10, 2014, Pages 1917-1923

  Sinn, M ^a   Denkert, C ^a   Striefler, J K ^a   Pelzer, U ^a   Stieler, J M ^a   Bahra, M ^a   Lohneis, P ^a   Dorken B ^a   Oettle, H ^a   Riess, H ^a   Sinn, B V ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

adjuvant therapy; CONKO 001; gemcitabine; pancreatic cancer; stroma; SMA

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; GEMCITABINE; ACTA2 PROTEIN, HUMAN; ACTIN; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; CELL DENSITY; CONTROLLED STUDY; DESMOPLASTIC STROMAL REACTION; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; PANCREATIC STELLATE CELL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOOTH MUSCLE FIBER; STROMA CELL; SURVIVAL PREDICTION; TISSUE MICROARRAY; TUMOR DIFFERENTIATION; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ANALOGS AND DERIVATIVES; CANCER GRADING; CANCER STAGING; CLINICAL TRIAL; ENZYME IMMUNOASSAY; FOLLOW UP; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PANCREATIC NEOPLASMS; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TUMOR INVASION; TUMOR MICROENVIRONMENT; VERY ELDERLY;

ACTINS; ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; STROMAL CELLS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84922481783     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.495     Document Type: Article

References (22)

1. DeJesus-Acosta A, O'Dwyer P, Ramanathan D (2014) A phase II study of vismodegib, a hedgehog pathway inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated pancreatic ductal adenocarcinoma. J Clin Oncol 2014(suppl 3): abstr 257
2. Delany AM (2010) Matricellular proteins osteopontin and osteonectin/SPARC in pancreatic carcinoma. Cancer Biol Ther 10: 65-67
3. Erkan M, Adler G, Apte MV, Bachem MG, Buchholz M, Detlefsen S, Esposito I, Friess H, Gress TM, Habisch H-J, Hwang RF, Jaster R, Kleeff J, Klöppel G, Kordes C, Logsdon CD, Masamune A, Michalski CW, Oh J, Phillips PA, Pinzani M, Reiser-Erkan C, Tsukamoto H, Wilson J (2012a) StellaTUM: current consensus and discussion on pancreatic stellate cell research. Gut 61: 172-178
4. Erkan M, Hausmann S, Michalski CW, Fingerle AA, Dobritz M, Kleeff J, Friess H (2012b) The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat Rev Gastroenterol Hepatol 9: 454-467
5. Erkan M, Michalski CW, Rieder S, Reiser-Erkan C, Abiatari I, Kolb A, Giese NA, Esposito I, Friess H, Kleeff J (2008) The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Clin Gastroenterol Hepatol 6: 1155-1161
6. Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA (2012) The pancreas cancer microenvironment. Clin Cancer Res 18: 4266-4276
7. Fujita H, Ohuchida K, Mizumoto K, Nakata K, Yu J, Kayashima T, Cui L, Manabe T, Ohtsuka T, Tanaka M (2010) alpha-Smooth muscle actin expressing stroma promotes an aggressive tumor biology in pancreatic ductal adenocarcinoma. Pancreas 39(8): 1254-1262
8. Garber K (2010) Stromal depletion goes on trial in pancreatic cancer. J Natl Cancer Inst 102: 448-450
9. Hamada S, Masamune A, Shimosegawa T (2013) Novel therapeutic strategies targeting tumor-stromal interactions in pancreatic cancer. Front Physiol 4: 331
10. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369: 1691-1703
11. Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias JL, Zhang H, Soon-Shiong P, Shi T, Rajeshkumar NV, Maitra A, Hidalgo M (2011) Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 29: 4548-4554
12. Infante JR, Matsubayashi H, Sato N, Tonascia J, Klein AP, Riall TA, Yeo C, Iacobuzio-Donahue C, Goggins M (2007) Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol 25: 319-325
13. Lunardi S, Muschel RJ, Brunner TB (2014) The stromal compartments in pancreatic cancer: are there any therapeutic targets?. Cancer Lett 343: 147-155
14. Lunevicius R, Nakanishi H, Ito S, Kozaki K, Kato T, Tatematsu M, Yasui K (2001) Clinicopathological significance of fibrotic capsule formation around liver metastasis from colorectal cancer. J Cancer Res Clin Oncol 127: 193-199
15. Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, Niedergethmann M, Zülke C, Fahlke J, Arning MB, Sinn M, Hinke A, Riess H (2013) Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 310: 1473-1481
16. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein W-O, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297: 267-277
17. Ram?rez N, Viúdez A, Hernández-Garc?a I, Guerrero D, Gómez-Dorronsoro M, Herrera FJ, Vila J, Beloki L, Ciaúrriz M, Mansilla C, Vera R (2014) Stellate cells, a point of light in the dark night of pancreatic cancer. Br J Cancer 111: 1676-1677
18. Seufferlein T, Porzner M, Becker T, Budach V, Ceyhan G, Esposito I, Fietkau R, Follmann M, Friess H, Galle P, Geißler M, Glanemann M, Gress T, Heinemann V, Hohenberger W, Hopt U, Izbicki J, Klar E, Kleeff J, Kopp I, Kullmann F, Langer T, Langrehr J, Lerch M, Löhr M, Lüttges J, Lutz M, Mayerle J, Michl P, Möller P, Molls M, Münter M, Nothacker M, Oettle H, Post S, Reinacher-Schick A, Röcken C, Roeb E, Saeger H, Schmid R, Schmiegel W, Schoenberg M, Siveke J, Stuschke M, Tannapfel A, Uhl W, Unverzagt S, van Oorschot B, Vashist Y, Werner J, Yekebas E (2013) [S3-guideline exocrine pancreatic cancer]. Z Für Gastroenterol 51: 1395-1440
19. Sinn M, Sinn BV, Striefler JK, Lindner JL, Stieler JM, Lohneis P, Bischoff S, Bläker H, Pelzer U, Bahra M, Dietel M, Dörken B, Oettle H, Riess H, Denkert C (2014) SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study. Ann Oncol 25: 1025-1032
20. Vonlaufen A, Phillips PA, Xu Z, Goldstein D, Pirola RC, Wilson JS, Apte MV (2008) Pancreatic stellate cells and pancreatic cancer cells: an unholy alliance. Cancer Res 68: 7707-7710
21. Wilson JS, Pirola RC, Apte MV (2014) Stars and stripes in pancreatic cancer: role of stellate cells and stroma in cancer progression. Front Physiol 5: 52
22. Yamao J, Toyokawa H, Kim S, Yamaki S, Satoi S, Yanagimoto H, Yamamoto T, Hirooka S, Matsui Y, Kwon A-H (2013) Activation of alpha-smooth muscle actin-positive myofibroblast-like cells after chemotherapy with gemcitabine in a rat orthotopic pancreatic cancer model. J Hepato Biliary Pancreat Sci 20: 206-213